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To identify rare causal variants in late-onset Parkinson disease (PD), we investigated an Austrian family with 16 affected individuals by
exome sequencing. We found a missense mutation, c.1858G>A (p.Asp620Asn), in the VPS35 gene in all seven affected family members
who are alive. By screening additional PD cases, we saw the same variant cosegregating with the disease in an autosomal-dominantmode
with high but incomplete penetrance in two further families with five and ten affected members, respectively. The mean age of onset in
the affected individuals was 53 years. Genotyping showed that the shared haplotype extends across 65 kilobases around VPS35.
Screening the entireVPS35 coding sequence in an additional 860 cases and 1014 controls revealed six further nonsynonymousmissense
variants. Three were only present in cases, two were only present in controls, and one was present in cases and controls. The familial
mutation p.Asp620Asn and a further variant, c.1570C>T (p.Arg524Trp), detected in a sporadic PD case were predicted to be damaging
by sequence-based andmolecular-dynamics analyses. VPS35 is a component of the retromer complex andmediates retrograde transport
between endosomes and the trans-Golgi network, and it has recently been found to be involved in Alzheimer disease.Parkinson’s disease (PD [MIM 168600]) is the second-most
common neurodegenerative disorder; it affects 1%–2% of
the population above the age of 60.1 It is characterized
by degeneration of dopaminergic neurons in the nigro-
striatal pathway and other monoaminergic cell groups in
the brainstem. This degeneration leads to bradykinesia,
resting tremor, muscular rigidity, and postural instability
as well as nonmotor symptoms. Up to 20% of cases with
PD are reported to be familial,2,3 but extended pedigrees
with clear Mendelian inheritance are rare. Genetic studies
have so far revealed mutations in five genes causing auto-
somal-recessive (PARK2 [MIM 602544], PINK1 [MIM
608309], PARK7 [MIM 602533]) or autosomal-dominant
(SNCA [MIM 163890], LRRK2 [MIM 609007]) forms of
PD.4–9 Whereas the autosomal-recessive forms with
early onset and SNCA missense mutations or duplica-
tions10 are rare, a single LRRK2 mutation (RefSeq number
NM_198578.3: c.6055G>A [p.Gly2019Ser]) accounts for
approximately 1% of sporadic cases of European
origin.11–13 A recent study revealed a strong association
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somal enzyme in the pathogenesis of PD.14,15 Genome-
wide association studies revealed several low-risk suscepti-
bility loci, among them LAMP3 [MIM 605883] and HIP1R
[MIM 605613], which have been reported to be implicated
in the lysosomal pathway.16–18
We identified an Austrian family in which 16 members
were affected by PD (family A, Figure 1). PD seemed to be
inherited in an autosomal-dominant mode with high
penetrance. Seven affected members were available for
clinical and DNA investigations. Six of them exhibited at
least three of the four cardinal signs of PD (akinesia, resting
tremor, rigidity, and postural instability) and showed
improvement after dopaminergic treatment. A single
affected individual had displayed action tremors since
childhood but developed L-Dopa-responsive resting
tremors and akinesia only at the age of 62 years. The
mean age of onset was 53 years (range 40–68 years) (Table
1). The clinical diagnosis of idiopathic PD was made by
movement-disorder specialists who used UK brain bank
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Figure 1. Pedigrees of Families A, B, and C
Unaffected familymembers are indicated by open symbols, affectedmembers by closed symbols. Asterisks denote individuals genotyped
for p.Asp620Asn. Tomaintain confidentiality, we have not shown genotypes of unaffected individuals. A questionmark within a symbol
denotes an unknown phenotype. Diagonal bars through symbols denote deceased individuals.consent. The study was approved by the institutional
review board of the Medizinische Universita¨t Wien and
the Hessische Landesa¨rztekammer Wiesbaden.
To identify the disease-causing variant, we selected two
second cousins (#3017 and #3020) for exome sequencing.
We assumed that any rare variants common in both indi-
viduals would be disease-causing candidates. Selecting
distantly relatedmembers of the pedigree shouldminimize
the proportion of alleles shared by descent. Exome
sequencing was performed on a Genome Analyzer IIx
system (Illumina) after in-solution enrichment of exonic
sequences (SureSelect Human All Exon 38Mb kit, Agilent).
We sequenced two lanes of a flowcell for both samples, each
as 54 bp paired-end runs. Read alignment was performed
with BWA (version 0.5.8) to the human genome assembly
hg19 (Table S1, available online). Single-nucleotide variants
and small insertions and deletions (indels) were detected
with SAMtools (v 0.1.7). We filtered called variants to
exclude those present in 72 control exomes from patients
with other unrelated diseases. We further excluded all vari-
ants that were present in dbSNP 131 and had an average
heterozygosity of more than 0.02. Variant annotation wasThe Amperformed with custom scripts. This approach left ten
heterozygous nonsynonymous variants shared by both
affected individuals (Table 2; see also Table S2).
Only a singleheterozygous variant in theVPS35 gene (Re-
fSeq number NM_018206.4: c.1858G>A [p.Asp620Asn])
fulfilled two further criteria of being possibly causative: (1)
it was found in all seven affected members investigated
and (2) was absent in approximately 680 KORA S4
general-population samples (Tables 2 and 3).20 We next
screened 486 unrelated PD patients from Austria for the
p.Asp620Asn variant by MALDI-TOF mass spectroscopy
(SequenomMassArray system).We detected two additional
index patients carrying this mutation (families B and C;
Figure 1 and Table 1). The variant was detected in all eight
affected individuals investigated in both families. It was
not present in a second set of 554 Austrian controls or in
an additional 1014 KORA-AGE controls (Table 3). The
variant was further detected in three clinically unaffected
family members in families A, B, and C. Because the
unaffected individuals are all younger than 60 years of
age, either they are all presymptomatic or the mutation is
nonpenetrant in these subjects.erican Journal of Human Genetics 89, 168–175, July 15, 2011 169
Table 1. Clinical Findings for PD Patients Carrying Variants in VPS35
Family Patient Variation AaO DD IS B R RT PI L-Dopa/DA Other Features
A 3017 p.Asp620Asn 48 7 B þ þ  þ þ
A 3019 p.Asp620Asn 40 5 B þ þ þ þ þ
A 3020 p.Asp620Asn 46 7 PI þ þ  þ þ
A 3021 p.Asp620Asn 68 16 PI þ þ þ þ þ
A 3049 p.Asp620Asn 49 4 RT þ þ þ  þ
A 3044 p.Asp620Asn 64 3 PI þ þ þ þ þ
A 3045 p.Asp620Asn 63 1 RT þ  þ  þ action tremor since
childhood
B 2056 p.Asp620Asn 61 15 RT þ þ þ þ þ fluctuations, dyskinesias
B 2057 p.Asp620Asn 56 8 RT þ þ þ þ þ fluctuations, dyskinesias
B 2098 p.Asp620Asn 46 0.5 RT   þ  untreated depression, action tremor,
pathologic DAT SPECT
B 2099 p.Asp620Asn 51 5 B þ þ þ  þ fluctuations, pathologic
DAT SPECT
C 3022 p.Asp620Asn 61 5 RT þ þ þ  þ dyskinesias
C 3055 p.Asp620Asn 46 12 RT þ þ þ  þ
C 3054 p.Asp620Asn 53 9 B þ þ   þ dyskinesias
C 3056 p.Asp620Asn 43 10 B þ þ þ þ þ dyskinesias
211 p.Arg524Trp 37 9 MG þ þ þ  þ mild action tremor since
youth; 75% motor
improvement on
levodopa-test; DBS for
fluctuations and
dyskinesias; pathologic
DAT SPECT
524 p.Leu774Met 51 7 RT þ þ þ  þ marked postural tremor
243 p.Leu774Met 73 9 RT þ þ þ þ þ dyskinesias, pathologic
DAT SPECT
806 p.Ile241Met 72 2 Postural
tremor
þ  þ þ þ hyposmia (6/12 sniffing
sticks), DAT SPECT
pathologic, pathologic
crying
90/05 p.Met57Ile 62 13 RT þ þ þ þ þ dementia (MMSE 23),
dysphagia and dysarthria,
hyposmia by history,
depression
Abbreviations are as follows: AaO, age at onset; DD, disease duration in years; IS, initial symptoms; B, bradykiesia; R, rigidity; RT, resting tremor; PI, postural insta-
bility; L-Dopa/DA, response to L-Dopa and/or dopamine agonist; MG, micrographia; DBS, deep brain stimulation.Cross-species alignment of VPS35 from plants, fungi,
invertebrates, and vertebrates showed complete conserva-
tion of amino acid Asp620 (Figure S1). The likely conse-
quence of the p.Asp620Asn variant was predicted to be
damaging by PolyPhen2,21 SNAP,22 and SIFT.23 We there-
fore concluded that the variant p.Asp620Asn is indeed
very likely to be causative for PD in families A, B, and C.
To determine whether the variant p.Asp620Asn occurred
on the same haplotype, we genotyped 20 individuals
from families A–C with oligonucleotide SNP arrays
(HumanOmni2.5-Quad, Illumina). Haplotyping and
linkage analysis were performed with the Merlin soft-
ware.24 The haplotypes carrying the variant p.Asp620Asn
in families A–C are depicted in Table S3. Family A and B170 The American Journal of Human Genetics 89, 168–175, July 15, 2shared a commonhaplotype across 21Mbbetweenmarkers
rs1072594 and rs4444336. FamilyC,however, showedonly
a common region of 65 kb across VPS35. Different alleles
were located at markers rs56168099 and rs74459547,
25 kb upstream and 11 kb downstream of VPS35, respec-
tively (Table S3). Because the two intragenic markers did
not differ, we could not determine whether the three fami-
lies shared an old commonhaplotype or whether themuta-
tion has recently arisen on two different haplotypes.
To assess the prevalence of other VPS35 mutations
among PD cases and the general population, we screened
all 17 coding exons for variations by dye-binding/high-
resolution DNA melting curve analysis (LightScanner HR
I 384, Idaho Technology) in 860 cases (484 Austrian and011
Table 2. Exome Sequencing: Rare, Heterozygous, Nonsynonymous Variations Shared by Two Individuals of Pedigree A
Gene Position (hg19) dbSNP Transcript
Variations Control Genotypes
SegregationNucleotide Amino Acid 1/1 1/2 2/2
PLK3 chr1:45270359 NM_004073.2 c.1543T>A p.Ser515Thr 669 0 0 4 of 7
C8A chr1:57383357 rs41285938 NM_000562.2 c.1723C>T p.Pro575Ser 5 of 7
ADCY10 chr1:167787479 rs41270737 NM_018417.4 c.4313A>G p.Asn1438Ser 2 of 7
LAMB2 chr3:49166460 NM_002292.3 c.1724G>A p.Arg575Gln 647 28 0 5 of 7
NOM1 chr7:156762317 NM_138400.1 c.2503G>A p.Ala835Thr 670 0 0 3 of 7
KIF22 chr16:29816237 NM_007317.1 c.1780G>A p.Asp594Asn 665 6 0 6 of 7
SEZ6L2 chr16:29899021 NM_012410.2 c.947G>A p.Arg316His 660 4 0 7 of 7
VPS35 chr16:46696364 NM_018206.4 c. 1858G>A p.Asp620Asn 1069a 0 0 7 of 7
NLRP1 chr17:5421150 NM_001033053.2 c.3985G>A p.Val1329Ile 666 4 0 3 of 7
NEURL4 chr17:7221197 NM_001005408.1 c.4109G>A p.Arg1370Gln 3 of 7
Rare variations revealed by exome sequencing were checked in 670 controls (KORA S4) by MALDI-TOF analysis. The variant allele was denoted as ‘‘2,’’ the refer-
ence allele as ‘‘1.’’
a This number includes additional 554 Austrian control individuals investigated by a TaqMan genotyping assay. Segregation shows the number of affected pedi-
gree A individuals who carry the variant allele.376 German cases) and 1014 controls. For controls, we
used a population-based cohort (KORA AGE) with
a mean age of 76 years but excluded eight individuals
known to be on medications for PD (Table 3). Exons 2
to 12 are located within a region that is duplicated 12
Mb upstream. Primers were designed to specifically
amplify these exons (Table S4). The screening revealedTable 3. Summary of the Samples Used in This Study
Cohort Sample Size Mean Age (SD) Females/Males
Austrian PD casesa 486 58.7 (11.3) 172/314
German PD casesb 376 71.1 (9.4) 119/257
KORA S4 controlsc 680 54.7 (11.9) 280/400
KORA-AGE controlsd 1014 76.0 (6.6) 508/505
Austrian controlse 554 46 (15.2) 254/300
Patients presenting with atypical or secondary (e.g., vascular) parkinsonian
disorders as well as patients with known mutations were excluded.
a The Austrian cases were recruited at the Department of Neurology,
Medizinische Universita¨t Wien, Vienna, as well as in affiliated departments on
a consecutive basis. A positive family history for PD was reported from 131
patients. A positive family history was defined by at least one other affected
first- or second-degree related family member.
b The German PD population originated from the Paracelsus-Elena Klinik,
Kassel, a hospital specializing in movement disorders.
c This control population was recruited from the KORA S4 survey, comprising
individuals who were aged 25–74 years and were examined during 1999–
2001.
d The KORA-AGE samples were collected in 2009 as a gender- and age-
stratified subsample of the KORA S1–S4 studies comprising participants born
before 1944. KORA S1–S4 surveys comprise four independent cross-sectional
population-based studies in the region of Augsburg, Southern Germany, and
were conducted in 5 year intervals. Patients for whom PD was suspected on
the basis of questionnaire data were excluded.
e These control samples were recruited through the Department of Neurology,
Medical University of Vienna, as subjects without known history of a neurolog-
ical disorder and included, for example, blood donors or unrelated compan-
ions or spouses of patients.
The Amsix further rare coding SNVs in addition to p.Asp620Asn
(Table 4). Including p.Asp620Asn, we identified four
different nonsynonymous missense variants only present
in cases, two only present in controls, and one present in
cases and controls. Two of the variants unique to PD cases
were predicted to be damaging by all three methods
(c.1858G>A [p.Asp620Asn]; c.1570C>T [p.Arg524Trp]),
and one was predicted by PolyPhen2 to be possibly
damaging (c.723T>G, p.Ile241Met). The other variants
were predicted to be benign by all methods. Family infor-
mation was only available for the patient carrying the
p.Arg524Trp variant. The only available family member
was her mother, aged 74 years. She was found to also carry
the variant and showed mild extrapyramidal signs,
including intermittent resting tremor of the left fingers
and mild postural tremor of both upper limbs, but no bra-
dykinesia. However, a DAT SPECT examination showed
normal striatal binding, excluding the possibility of an
early stage of PD in this subject. Of note, the screening
did not reveal any common nonsynonymous coding
SNVs. Furthermore, common nonsynonymous coding
SNVs were not found in the 72 control exomes from
patients with other unrelated diseases, nor were any re-
corded in the dbSNP database (version 131).
VPS35 is a component of the retromer complex and is
involved in retrograde transport from the endosomes back
to the trans-Golgi network.25 This multi-protein complex
consists of the cargo-recognition VPS26-VPS29-VPS35
heterotrimer and a membrane-targeting heterodimer or
homodimer of SNX1 and/or SNX2 (vps5).25,26 All proteins
involved are evolutionarily conserved and have been
previously described in Saccharomyces cerevisiae. The best
characterized cargo proteins of the retromer complex are
the cation-independent mannose 6-phosphate receptorerican Journal of Human Genetics 89, 168–175, July 15, 2011 171
Table 4. Rare VPS35 Variants in Cases and Controls
ID Cases
KORA AGE
Controls
Heterozygous
Nucleotide
Change
Amino Acid
Change
Predicted
Impact
on Protein
Exon/
Intron
Genomic
Position
(hg19, chr16)
KORA S4
Controls
1/1 1/2 2/2
Nonsynonymous (i) (ii) (iii)
- 1 c.151G>A p.Gly51Ser þ þ þ 3 46,716,,039
90/05 - c.171G>A p.Met57Ile þ þ þ 3 46,716,019 670 0 0
- 1 c.245C>G p.Thr82Arg þ þ þ 4 46,715,367
806 - c.723T>G p.Ile241Met 5 þ þ 7 46,711,308 667 0 0
[211] - c.1570C>T p.Arg524Trp    13 46,702,919 671 0 0
[Families A-C] - c.1858G>A p.Asp620Asn    15 46,696,364 669 0 0
243, 524 2 c.2320C>A p.Leu774Met þ þ þ 17 46,694,455
Synonymous
53097 - c.492A>G p.Glu164Glu 5 46,714,597 671 0 0
- 1 c.954A>T p.Gly315Gly 9 46,708,542
53496 - c.1881C>T p.Ala627Ala 15 46,696,341 668 5 0
45, 117, 53626 1 c.2145A>G p.Leu715Leu 16 46,695,696 666 2 0
53667 - c.2241C>T p.Ile747Ile 17 46,694,534 667 2 0
53063 - c.2346A>G p.Glu782Glu 17 46,694,429 671 0 0
- 1 c.2361G>A p.Glu787Glu 17 46,694,414
Noncoding
2212 2 c.1-35C>T 50UTR 46,723,080 667 2 0
- 2 c.1-29C>T 50UTR 46,723,074
95, 2206 3 c.3þ24A>G 1 46,723,019 662 6 0
159, 528 1 c.102þ33G>A 2 46,717,387 668 2 0
[157, 2023] - c.103-77T>C 3 46,716,164 668 0 0
- 1 c.199þ9T>G 3 46,715,982
213 - c.506þ6T>C 5 46,714,577 644 0 0
53093 - c.720þ18C>T 6 46,712,773
- 1 c.914þ38T>C 8 46,710,457
52824 - c.1161-87A>C 10 46,706,471
52791 - c.1161-70G>A 10 46,706,454 668 0 0
- 1 c.1368þ16C>T 11 46,706,161
[2028] - c.1369-11G>A 12 46,705,783 669 0 0
- 1 c.1525-17delT 12 46,702,985
- 1 c.1647þ14T>C 13 46,702,828
320 - c.2212-45T>C 16 46,694,608 670 0 0
[352] - c.2391þ7A>G 30UTR 46,694,377
- 1 c.2391þ8A>G 30UTR 46,694,376
Variants for 863 cases and 1014 KORA AGE controls were determined by dye-binding/high-resolution DNA melting curve analysis and confirmed by Sanger
sequencing. The table lists the case ID and the number of detected variant alleles of the cases and KORA AGE samples, respectively. Genotypes of identified variants
were further investigated by MALDI-TOF analysis in approximately 680 KORA S4 controls. For the KORA S4 samples, the variant allele was denoted as ‘‘2,’’ the
reference allele as ‘‘1.’’ cDNA numbering is based on reference gene NM_018206.4 for VPS35, where þ1 corresponds to the A of ATG start translation codon.
Familial cases are given in square brackets. Three methods were used for predicting the impact of SNPs on the protein. (1) PolyPhen2, (2) SNAP, and (3) SIFT;
‘‘þ’’ indicates a benign impact, ‘‘5’’ indicates a possibly damaging impact, and ‘‘’’ indicates a damaging impact. We detected a further nonsynonymous variant
(c.1093C>T [p.Arg365Cys], genomic position 46,708,293) in a patient carrying two PARKIN variants (c.exon3_4del and p.Arg275Trp). This variant was not
present in 670 KORA S4 and 1014 KORA AGE controls. It is predicted to be possibly damaging by all three methods. This patient’s brother is also affected by
PD. He carries the 2 PARKIN variants but not the VPS35 variant.
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Figure 2. Hydrogen-Bonding Capacities for Wild-Type Asp620
and Arg524 and the Variants p.Asp620Asn and p.Arg524Trp
Hydrogen bonds (HB) are shown as red dashed lines. Asp60 and
Arg524 are in green; p.Asp620Asn and p.Arg524Trp are in orange.
(A) Asp620 forms a HB to Lys622 and shows an additional salt-
bridge interaction. p.Asp620Asn forms fewer HBs, and no electro-
static interaction is possible.
(B) Arg524 forms a HB network with Asp483 and Asp486. This
network is broken by the p.Arg524Trp substitution.(CI-MPR)27 and Vps10p in mammals and Saccharomyces
cerevisiae, respectively; these proteins transport hydroxy-
lases to the lysosomesor lysosomal vacuoles. Recently, addi-
tional cargo proteins and functions of VPS35 have been
described.28,29 Most interesting in our context is the
involvement of the retromer into the retrograde transport
of SORL1, a VPS10P-domain receptor protein that has
been implicated inAlzheimer disease.30,31 The crystal struc-
ture of the C-terminal part of VPS35 has been resolved.32
The three variants p.Asp620Asn, p.Arg524Trp, and
p.Leu774Met are located in this part of the protein, and
we have investigated their impact on protein stability by
usingmolecular dynamics (MD) simulations.Wemanually
introduced the mutations to the crystal structure and
modeled the side chains by using scwrl 4.0.33 All MD simu-
lations were performed via GROMACS 4.5,34 with the all-
atom force field AMBER0335 and the water model TIP3P36
as parameters. All three proteins are found on the edge of
helices interacting with VPS29. Wild-type residue Asp620
forms frequent hydrogen bonds (HBs) to Lys622, but these
bonds are less frequent in the p.Asp620Asn variant
(Figure 2A). Similarly, Arg524 is involved in a triple HB
network together with residues Asp483 and Asp486, but
this network is broken by the introduction of p.Arg524Trp
(Figure 2B). Both changes result in the loss of salt bridges
and cause the protein to be locally more flexible, as shown
by root-mean-square fluctuation (RMSF) profiles (Figure S2).
In contrast to the effect predicted for p.Arg524Trp and
p.Asp620Asn, the p.Leu774Met variant was not predicted
to have a strong impact on protein stability.
In summary, we identified rare VPS35 missense variants
that are potentially pathogenic. One of these variants,
p.Asp620Asn, cosegregates with late-onset PD in threeThe Amunrelated families. The observation that the three families
share only a small common haplotype across VPS35, the
high conservation of VPS35, the predicted structural
changes, and the protein’s known involvement in lyso-
somal trafficking together provide strong support for the
p.Asp620Asn variant’s being causative for late-onset PD,
although we identified only a single familial mutation.
The penetrance of p.Asp620Asn is high but not complete
and might be lower for the other variants. The proportion
of PD caused by VPS35 variants is expected to be low.
Although exome sequencing provides perfect access to
rare-variant detection, both large families and large collec-
tions of cases and controls remain a crucial resource for the
identification of disease genes.Supplemental Data
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